Telomir announces preclinical osteosarcoma data: Telomir-Zn inhibits growth in human and canine cell lines

Telomir Pharmaceuticals, Inc.

Ohio State study: Telomir-Zn inhibited growth in HOS (human), D17 (canine), and Abrams (canine) osteosarcoma cell lines at similar low drug concentrations.
Company assessing potential in vivo canine osteosarcoma efficacy study with Ohio State; TNBC Phase 1/2 enrollment advancing toward site initiation.
Lead investigator Shay Bracha, DVM, DACVIM (Oncology); findings support translational development in both veterinary and human osteosarcoma.
TNBC program remains immediate focus under active FDA-cleared IND; osteosarcoma is a parallel Track 2 development pathway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.